Natera Inc

Stock Chart, Company Information, and Scan Results

$162.86(as of Sep 29, 3:59 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Natera Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$162.86
Ticker SymbolNTRA
ExchangeNasdaq
SectorHealthcare
IndustryDiagnostics & Research
Employees4,424
CountyUSA
Market Cap$22,367.3M
EBIDTA-262.0M
10-Day Moving Average171.71
P/E Ratio-87.84
20-Day Moving Average170.83
Forward P/E Ratio0.00
50-Day Moving Average158.77
Earnings per Share-1.91
200-Day Moving Average158.56
Profit Margin-18.47%
RSI44.34
Shares Outstanding137.2M
ATR5.31
52-Week High183.00
Volume1,087,923
52-Week Low117.27
Most Recent Support Level160.02
Book Value1,246.2M
Most Recent Resistance Level181.85
P/B Ratio17.85
Upper Keltner182.79
P/S Ratio11.32
Lower Keltner158.87
Debt-to-Equity Ratio182.79
Next Earnings Date11/05/2025
Cash Surplus615.2M
Next Ex-Dividend DateUnknown

Natera, Inc., a diagnostics company, provides molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera molecular residual disease test for assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based genomic profiling test, that provides insight into genomic alterations and biomarkers; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product. It serves independent laboratories, national and regional reference laboratories, medical centers and physician practices, research laboratories, and pharmaceutical companies through its direct sales force, and a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.

Natera Inc In Our Stock Scanner

As of Sep 30, 2025
example chart graphic
Scan Name: Golden CrossScan Type: Stock Indicator Scans
As of ---
As of ---
As of ---
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.